SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Boyle F.)
 

Search: WFRF:(Boyle F.) > (2015-2019) > Adjuvant ovarian fu...

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Phillips, K. A. (author)
Regan, M. M. (author)
Ribi, K. (author)
show more...
Francis, P. A. (author)
Puglisi, F. (author)
Bellet, M. (author)
Spazzapan, S. (author)
Karlsson, Per, 1963 (author)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
Budman, D. R. (author)
Zaman, K. (author)
Abdi, E. A. (author)
Domchek, S. M. (author)
Feng, Y. (author)
Price, K. N. (author)
Coates, A. S. (author)
Gelber, R. D. (author)
Maruff, P. (author)
Boyle, F. (author)
Forbes, J. F. (author)
Ahles, T. (author)
Fleming, G. F. (author)
Bernhard, J. (author)
Co, Soft Investigators (author)
show less...
 (creator_code:org_t)
2016-04-19
2016
English.
In: British Journal of Cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 114:9, s. 956-964
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen + OFS, exemestane + OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen + OFS and exemestane + OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean +/- s.d., -0.21 +/- 0.92 vs -0.04 +/- 0.49, respectively, P = 0.71, effect size = -0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

breast cancer
ovarian function
cognitive function
quality of life
premenopausal
GnRH agonist
tamoxifen
exemestane
endocrine therapy
premenopausal women
randomized-trials
young-women
impairment
chemotherapy
exemestane
menopause
performance
alprazolam
Oncology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view